Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelos Appoints Industry Veteran to Lead Strategic Realignment
Novelos Appoints Industry Veteran to Lead Strategic Realignment MADISON, Wisc. (October 9, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT) announced that the Board of Directors, on October 4, 2013, appointed Dr. Simon Pedder as Acting Chief Executive Officer and elected him a Director, replacing
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION
NOVELOS THERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION MADISON, Wisc. (July 29, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, the company’s President and CEO and a
View HTML
Toggle Summary NOVELOS THERAPEUTICS PROVIDES PRODUCT PIPELINE UPDATE
NOVELOS THERAPEUTICS PROVIDES PRODUCT PIPELINE UPDATE To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 Evaluating I-131-CLR1404 (HOT) Potential Phase 2 Indications and Trial Designs To File CLR1502 (GLOW2) IND for Intraoperative Tumor Margin Illumination by End
View HTML
Toggle Summary NOVELOS THERAPEUTICS CLOSES $5.5 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS CLOSES $5.5 MILLION PUBLIC OFFERING MADISON, Wisc. (February 21, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a public offering of 11,000,000 units at
View HTML
Toggle Summary NOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING
NOVELOS THERAPEUTICS PRICES $5.5 MILLION PUBLIC OFFERING MADISON, Wisc. (February 13, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT THE 15th ANNUAL BIO CEO & INVESTOR CONFERENCE ON FEBRUARY 11
NOVELOS THERAPEUTICS TO PRESENT AT THE 15th ANNUAL BIO CEO & INVESTOR CONFERENCE ON FEBRUARY 11 MADISON, Wisc. (February 4, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S.
View HTML
Toggle Summary NOVELOS THERAPEUTICS PRESENTS DIAPEUTIC TECHNOLOGY PLATFORM AT EMIT: TARGETED RADIOTHERAPY INTERNATIONAL CONFERENCE
NOVELOS THERAPEUTICS PRESENTS DIAPEUTIC TECHNOLOGY PLATFORM AT EMIT: TARGETED RADIOTHERAPY INTERNATIONAL CONFERENCE Oral Presentation Highlights Cancer-Targeted PET Imaging, Therapeutic and Optical Imaging Compounds that Offer Broad-Spectrum Diagnosis and Treatment of Solid Tumors MADISON, Wisc.
View HTML
Toggle Summary NOVELOS THERAPEUTICS TO PRESENT AT THE BENCHMARK 2012 MICRO CAP DISCOVERY INVESTOR CONFERENCE ON NOVEMBER 29
NOVELOS THERAPEUTICS TO PRESENT AT THE BENCHMARK 2012 MICRO CAP DISCOVERY INVESTOR CONFERENCE ON NOVEMBER 29 MADISON, Wisc. (November 27, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that
View HTML
Toggle Summary NOVELOS THERAPEUTICS CLOSES $2 MILLION PRIVATE PLACEMENT
NOVELOS THERAPEUTICS CLOSES $2 MILLION PRIVATE PLACEMENT Initiates Build-out of Manufacturing Facility for I-124-CLR1404 (LIGHT) MADISON, Wisc. (November 5, 2012) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer,
View HTML
Toggle Summary NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN SOLID TUMOR IMAGING TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER
NOVELOS THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN SOLID TUMOR IMAGING TRIAL WITH I-124-CLR1404 (LIGHT) CANCER-TARGETED PET IMAGING AGENT AT UW CARBONE CANCER CENTER Expects Initial Imaging Results in First Quarter 2013 MADISON, Wisc. (October 25, 2012) – Novelos Therapeutics, Inc.
View HTML